Vaccine competition: Sanofi shelves mRNA-based Covid jab work
![](https://www.cityam.com/wp-content/uploads/2021/09/tagreuters.com2021binary_LYNXMPEH3P0LK-VIEWIMAGE.jpg?w=450)
French pharmaceutical giant Sanofi has shelved plans for its own mRNA-based Covid-19 jab due to the vaccine-success and dominance of rivals Pfizer and Moderna.
Instead, Sanofi is set to focus on a different coronavirus vaccine making approach with its British partner GlaxoSmithKline (GSK).
It signals the growing weight of the companies, namely BioNTech-Pfizer, Moderna and Oxford-AstraZeneca, that spearheaded the widespread Covid-19 vaccine manufacturing process.
As the alliance between BioNTech and Pfizer has already seen a near 1.5bn doses delivered to countries around the world.
It comes despite positive interim results for the phase I/II of its study.
The news gave Sanofi shares a slight boost, as it’s work with GSK is already undergoing mass trials and it will likely mean the firm can better streamline its costs.